News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LFB Biotechnologies's Recombinant Anti-CD20 Monoclonal Antibody is Granted Orphan Drug Status in Europe for Chronic Lymphocytic Leukemia



11/25/2009 9:05:32 AM

LES ULIS, France--(BUSINESS WIRE)--The recombinant anti-CD20 monoclonal antibody produced by LFB Biotechnologies received orphan drug status for the treatment of Chronic Lymphocytic Leukemia (CLL). This approval from the EMEA’s Committee for Orphan Medicinal Products (COMP) was handed down on last October 7th.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES